Acadia Healthcare Company, Inc. 00404A109 05/06/2026 Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 108986.0 0.0 AGAINST 108986.0 AGAINST ACADIA Pharmaceuticals Inc. 004225108 05/29/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 12967.0 0.0 FOR 12967.0 FOR Agilent Technologies, Inc. 00846U101 03/18/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 41500.0 0.0 FOR 41500.0 FOR Akero Therapeutics, Inc. 00973Y108 12/02/2025 To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 14061.0 0.0 FOR 14061.0 FOR Arbutus Biopharma Corporation 03879J100 05/26/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular. SECTION 14A SAY-ON-PAY VOTES ISSUER 115940.0 0.0 FOR 115940.0 FOR Boston Scientific Corporation 101137107 04/30/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 45000.0 0.0 FOR 45000.0 FOR Cencora, Inc. 03073E105 03/05/2026 Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 9400.0 0.0 FOR 9400.0 FOR Centene Corporation 15135B101 05/12/2026 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 55893.0 0.0 FOR 55893.0 FOR CG Oncology, Inc. 156944100 06/04/2026 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1288948.0 0.0 FOR 1288948.0 FOR CG Oncology, Inc. 156944100 06/04/2026 To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1288948.0 0.0 1 YEAR 1288948.0 FOR Corcept Therapeutics Incorporated 218352102 05/21/2026 To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 30000.0 0.0 FOR 30000.0 FOR Corvus Pharmaceuticals, Inc. 221015100 06/11/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 80562.0 0.0 FOR 80562.0 FOR DexCom, Inc. 252131107 05/27/2026 To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 90000.0 0.0 FOR 90000.0 FOR Dianthus Therapeutics, Inc. 252828108 05/21/2026 To approve, on an advisory basis, the compensation paid to our named executive officers; and SECTION 14A SAY-ON-PAY VOTES ISSUER 204591.0 0.0 FOR 204591.0 FOR Doximity, Inc. 26622P107 08/28/2025 To approve, on a non-binding advisory basis, the compensation paid to the Company s named executive officers for the fiscal year ended March 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 49837.0 0.0 FOR 49837.0 FOR Encompass Health Corporation 29261A100 05/07/2026 An advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 42000.0 0.0 FOR 42000.0 FOR Enliven Therapeutics, Inc. 29337E102 06/09/2026 To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 400000.0 0.0 AGAINST 400000.0 AGAINST Enliven Therapeutics, Inc. 29337E102 06/09/2026 To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 400000.0 0.0 1 YEAR 400000.0 FOR Gilead Sciences, Inc. 375558103 04/30/2026 To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 16290.0 0.0 FOR 16290.0 FOR Hims & Hers Health, Inc. 433000106 06/11/2026 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 122200.0 0.0 AGAINST 122200.0 AGAINST Intellia Therapeutics, Inc. 45826J105 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 52558.0 0.0 FOR 52558.0 FOR Jazz Pharmaceuticals Public Limited Company G50871105 07/24/2025 To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 11695.0 0.0 FOR 11695.0 FOR Karyopharm Therapeutics Inc. 48576U205 05/21/2026 To approve, on an advisory basis, the compensation of our named executive officers, as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 164587.0 0.0 AGAINST 164587.0 AGAINST Kenvue Inc. 49177J102 01/29/2026 To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Kenvue Inc.'s named executive officers that is based on or otherwise relates to the transactions contemplated by the Merger Agreement. SECTION 14A SAY-ON-PAY VOTES ISSUER 307217.0 0.0 FOR 307217.0 FOR Kenvue Inc. 49177J102 05/21/2026 Approve, on a non-binding advisory basis, the compensation of Kenvue Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 157800.0 0.0 FOR 157800.0 FOR McKesson Corporation 58155Q103 07/30/2025 Advisory Vote to Approve the Company's Executive Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 11108.0 0.0 FOR 11108.0 FOR Medtronic plc G5960L103 10/16/2025 Approving, on an advisory basis, the Company's executive compensation; SECTION 14A SAY-ON-PAY VOTES ISSUER 149763.0 0.0 FOR 149763.0 FOR MoonLake Immunotherapeutics 61559X104 06/04/2026 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 50000.0 0.0 FOR 50000.0 FOR Natera, Inc. 632307104 06/11/2026 To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 9000.0 0.0 FOR 9000.0 FOR Natera, Inc. 632307104 06/11/2026 To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 9000.0 0.0 1 YEAR 9000.0 FOR Oruka Therapeutics, Inc. 687604108 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 760424.0 0.0 FOR 760424.0 FOR Palvella Therapeutics, Inc. 697947109 06/10/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 49275.0 0.0 FOR 49275.0 FOR Palvella Therapeutics, Inc. 697947109 06/10/2026 Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 49275.0 0.0 1 YEAR 49275.0 FOR Perspective Therapeutics, Inc. 46489V302 05/27/2026 To approve, on a non-binding advisory basis, the frequency of advisory stockholder votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 5777935.0 0.0 1 YEAR 5777935.0 FOR Phathom Pharmaceuticals, Inc. 71722W107 05/19/2026 To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 249390.0 0.0 AGAINST 249390.0 AGAINST Repligen Corporation 759916109 05/14/2026 Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 41920.0 0.0 FOR 41920.0 FOR SCYNEXIS, Inc. 811292200 06/25/2026 To vote, on an advisory basis, on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2081660.0 0.0 FOR 2081660.0 FOR SCYNEXIS, Inc. 811292200 06/25/2026 To vote, on an advisory basis, on the frequency of future advisory voting on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2081660.0 0.0 1 YEAR 2081660.0 FOR Structure Therapeutics Inc. 86366E106 06/17/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 48000.0 0.0 FOR 48000.0 FOR Tempus AI, Inc. 88023B103 05/21/2026 To consider a non-binding advisory vote on the frequency of future stockholder votes to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 10541.0 0.0 1 YEAR 10541.0 AGAINST Teva Pharmaceutical Industries Ltd. 881624209 05/28/2026 To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 450100.0 0.0 FOR 450100.0 FOR Trevi Therapeutics, Inc. 89532M101 06/03/2026 Approval, on an advisory basis, of the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 6660.0 0.0 FOR 6660.0 FOR UnitedHealth Group Incorporated 91324P102 06/01/2026 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 3800.0 0.0 AGAINST 3800.0 AGAINST Vir Biotechnology, Inc. 92764N102 05/26/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 650000.0 0.0 AGAINST 650000.0 AGAINST